FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...
FibroBiologics (FBLG) announced the filing of a Phase 1/2 Investigational New Drug application with the U.S. Food and Drug Administration seeking ...
Insects thrive in incredibly diverse and challenging environments. While we now know that nutrient-sensing pathways, ...
Intestinal Stem Cells (ISCs) derived from a patient's own cells have garnered significant attention as a new alternative for treating intractable intestinal diseases due to their low risk of rejection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback